Product Description
Secukinumab is a novel biologic agent that specifically targets interleukin-17 (IL-17) involved in a pathological process. It is a fully human monoclonal antibody. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30725776/)
Mechanisms of Action: IL17A Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Lebanon, Lithuania, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Russia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Arthritis, Juvenile|Arthritis, Psoriatic|Enthesopathy|Giant Cell Arteritis|Hidradenitis Suppurativa|Inflammation|Lupus Nephritis|Polymyalgia Rheumatica|Psoriasis|Spondylarthritis|Spondylitis|Spondylitis, Ankylosing|Spondyloarthritis|Tendinopathy|Thyroid Eye Disease
Phase 2: Lichen Planus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SELUNE EXTENSION | P3 |
Active, not recruiting |
Lupus Nephritis |
2029-06-06 |
|
| jRCT2021220032 | P3 |
Active, not recruiting |
Lupus Nephritis |
2029-04-30 |
|
| CAIN457C22301E1 | P3 |
Unknown Status |
Polymyalgia Rheumatica |
2028-05-08 |
|
| jRCT2031240079 | P3 |
Recruiting |
Polymyalgia Rheumatica |
2028-02-29 |